Juno Capital partner Edward Rudd believes that investing in medtech offers not only a long-term strategy for allocating capital, but an altruistic relief for investors.
Juno Capital set out to spot investment opportunities that other venture capital funds when Julian Hickman and Edward Rudd founded the VC firm in 2011.
Join thousands of industry professionals who rely on Medtech Insight for daily insights
Already a subscriber?
Freenome plans to file for US FDA approval of its blood-based screening test for colorectal cancer mid-year. If cleared, the test would rival Guardant Health’s Shield, the first FDA-cleared blood test for primary screening of colorectal cancer. Exact Sciences is also in the race to bring a blood-based colorectal screening test to market.
Nawal Ouzren, Sensorion CEO and director, shared the latest industry reaction to US FDA layoffs at the McDermott Will & Emery European Health and Life Sciences Symposium in Paris.
Egg Medical is ramping up efforts to expand international sales of its EggNest scatter radiation protection system to shield X-ray procedure room staff without disrupting workflow. Medtech Insight sat down with Bob Wilson, Egg Medical’s CEO, to discuss the various EggNest systems, marketing opportunities and the competitive landscape.
